株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ピーナッツ・アレルギー : パイプライン分析

Peanut Allergy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 251569
出版日 ページ情報 英文 92 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
ピーナッツ・アレルギー : パイプライン分析 Peanut Allergy - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 92 Pages
概要

ピーナッツ・アレルギーは特に子どもによく見られます。 ピーナッツへのアレルギー反応は、通常摂取後数分内に起こり、症状は軽度なものから重度のものまで分かれます。 ピーナッツ・アレルギーの兆候および症状は、口および喉周辺にじんましんや赤くなったりむくんだり、かゆかったりヒリヒリしたり、下痢、胃痙攣、吐き気あるいは嘔吐のような消化器官の問題が起きたり、喉が締まったり、息切れあるいは息がぜいぜい音を立てたり、鼻水が出たりします。

当レポートでは、ピーナッツ・アレルギーの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ピーナッツ・アレルギー 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • BioLingus AG
  • BioTech Tools s.a.
  • DBV Technologies S.A.
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • aldesleukin
  • ピーナッツ・アレルギーのアレルゲン
  • AR-101
  • ARA-LAMP-Vax
  • DBV-712
  • DN-1017
  • ピーナッツ・アレルギー/喘息向け CYP11A1 阻害薬
  • 呼吸器系・ 免疫疾患向け PIM-1 キナーゼ阻害薬
  • PER-1080
  • pnut-ASIT
  • ピーナッツ・アレルギー向け組み換えタンパク質
  • ピーナッツ・アレルギー 向け組み換えベクターワクチン
  • VTC-064

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8594IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 5 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Peanut Allergy.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peanut Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Peanut Allergy - Overview
    • Pipeline Products for Peanut Allergy - Comparative Analysis
  • Peanut Allergy - Therapeutics under Development by Companies
  • Peanut Allergy - Therapeutics under Investigation by Universities/Institutes
  • Peanut Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Peanut Allergy - Products under Development by Companies
  • Peanut Allergy - Products under Investigation by Universities/Institutes
  • Peanut Allergy - Companies Involved in Therapeutics Development
    • Adverum Biotechnologies, Inc.
    • Aimmune Therapeutics, Inc.
    • Alfacyte Ltd
    • Allergy Therapeutics Plc
    • AnaptysBio, Inc.
    • Aravax Pty Ltd
    • Array BioPharma Inc.
    • ASIT biotech s.a.
    • Astellas Pharma Inc.
    • BioLingus AG
    • DBV Technologies S.A.
    • HAL Allergy BV
    • Sanofi
  • Peanut Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANB-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANN-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-460770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DBV-712 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HALMPE-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peanut Allergy Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PER-1080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pnut-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyvac Peanut - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Peanut Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTC-064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peanut Allergy - Dormant Projects
  • Peanut Allergy - Discontinued Products
  • Peanut Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
      • Oct 02, 2016: Immunomic Therapeutics Scientist Presenting at International Society for Vaccines Annual Congress
      • Sep 28, 2016: Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
      • Sep 20, 2016: Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S.
      • Aug 18, 2016: Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
      • Aug 01, 2016: DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy
      • Jul 05, 2016: DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
      • Jun 27, 2016: DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children
      • Jun 21, 2016: Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer
      • Jun 21, 2016: DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere
      • Jun 15, 2016: DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression
      • Jun 13, 2016: Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
      • Jun 07, 2016: Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology Congress 2016
      • Jun 07, 2016: DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board
      • Jun 01, 2016: DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peanut Allergy, H2 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Peanut Allergy - Pipeline by Adverum Biotechnologies, Inc., H2 2016
  • Peanut Allergy - Pipeline by Aimmune Therapeutics, Inc., H2 2016
  • Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2016
  • Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Peanut Allergy - Pipeline by AnaptysBio, Inc., H2 2016
  • Peanut Allergy - Pipeline by Aravax Pty Ltd, H2 2016
  • Peanut Allergy - Pipeline by Array BioPharma Inc., H2 2016
  • Peanut Allergy - Pipeline by ASIT biotech s.a., H2 2016
  • Peanut Allergy - Pipeline by Astellas Pharma Inc., H2 2016
  • Peanut Allergy - Pipeline by BioLingus AG, H2 2016
  • Peanut Allergy - Pipeline by DBV Technologies S.A., H2 2016
  • Peanut Allergy - Pipeline by HAL Allergy BV, H2 2016
  • Peanut Allergy - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Peanut Allergy - Dormant Projects, H2 2016
  • Peanut Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Peanut Allergy, H2 2016
  • Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top